Silver Book

Silver Book Fact

Cost-effectiveness of SAVR

The cost-effectiveness ratio for surgical aortic valve replacement (SAVR), compared to no surgery, was estimated at $13,528 per quality-adjusted life year (QALY) (~$17,225 in 2017 dollars).

Cost-Effectiveness of Aortic Valve Replacement in the Elderly: An introductory story. J Thorac Cardiovasc Surg. 2007; 133(3): 608-13. http://www.jtcvsonline.org/article/S0022-5223(06)02087-3/fulltext

Reference

Title
Cost-Effectiveness of Aortic Valve Replacement in the Elderly: An introductory story
Publication
J Thorac Cardiovasc Surg
Publication Date
2007
Volume & Issue
Volume 133, Issue 3
Pages
608-13
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Publications

Aortic Stenosis Fact Sheet

 https://www.silverbook.org/wp-content/uploads/2017/10/AS-FS-cover.png Thumbnail

Related Facts

  • Undertreatment of patients with sSAS
    AS is often undertreated — one study found that 56% of severe symptomatic aortic stenosis (sSAS) patients referred to a cardiothoracic surgeon were not operated on.  
  • Cost-effectiveness of TAVR in sSAS patients
    Patients with severe symptomatic aortic stenosis (sSAS) considered to be at high surgical risk who underwent transcatheter aortic valve replacement (TAVR) experienced lifetime incremental cost-effectiveness ratios of $55,090 per QALY…  
  • TAVR v. SAVR in Intermediate-Risk SAS Patients
    At 1-year, severe aortic stenosis (SAS) patients with intermediate surgical mortality risk who underwent transcatheter aortic valve replacement (TAVR), had all-cause mortality rates of 7.4% (compared to 13% for surgical…  
  • Improvements in QoL from TAVR in SAS patients
    Symptomatic aortic stenosis (SAS) patients who underwent transcatheter aortic valve replacement (TAVR) experienced quality of life (QoL) improvements from 5.3 at baseline (10 point scale with 10=best imaginable health state)…  
  • TAVR Success in sSAS Patients
    A study of severe symptomatic aortic stenosis (sSAS) patients who received transcatheter aortic valve replacement (TAVR) found 30-day mortality of 2.2% for those who were high risk of surgical mortality/inoperable,…